Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-009807
Filing Date
2022-05-13
Accepted
2022-05-13 08:19:08
Documents
62
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q pyxs-20220331.htm   iXBRL 10-Q 2083283
2 EX-10.1 pyxs-ex10_1.htm EX-10.1 586835
3 EX-31.1 pyxs-ex31_1.htm EX-31.1 19066
4 EX-31.2 pyxs-ex31_2.htm EX-31.2 19071
5 EX-32.1 pyxs-ex32_1.htm EX-32.1 12268
6 EX-32.2 pyxs-ex32_2.htm EX-32.2 11596
7 GRAPHIC img30572168_0.jpg GRAPHIC 29481
  Complete submission text file 0000950170-22-009807.txt   6874516

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pyxs-20220331_pre.xml EX-101.PRE 265858
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pyxs-20220331_lab.xml EX-101.LAB 347213
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT pyxs-20220331_def.xml EX-101.DEF 153678
11 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pyxs-20220331.xsd EX-101.SCH 37639
12 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT pyxs-20220331_cal.xml EX-101.CAL 23662
56 EXTRACTED XBRL INSTANCE DOCUMENT pyxs-20220331_htm.xml XML 809141
Mailing Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140
Business Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 (617) 221-9059
Pyxis Oncology, Inc. (Filer) CIK: 0001782223 (see all company filings)

EIN.: 831160910 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40881 | Film No.: 22920340
SIC: 2834 Pharmaceutical Preparations